Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IDT Biologika

- PMLiVE

NHS to move ahead with Pfizer/BioNTech bivalent COVID-19 vaccine roll-out

The autumn booster programme launches today

- PMLiVE

Novavax’s COVID-19 vaccine candidate receives CHMP recommendation for use as a booster

The protein-based vaccine induced a ‘robust antibody response’ when used as a heterologous third booster dose, data from a UK-sponsored trial showed

- PMLiVE

Pfizer/BioNTech BA.1 COVID-19 booster receives CHMP recommendation

If an authorisation is granted, doses of the bivalent booster will be available to all 27 EU member states

- PMLiVE

Moderna’s Omicron BA.1 targeting bivalent booster recommended by CHMP for use in EU

Results from a phase 2/3 trial demonstrated mRNA-1273.214 had superior neutralising antibody response against Omicron compared to the currently authorised booster

- PMLiVE

Moderna granted FDA authorisation for emergency use of BA.4/BA.5-targeting bivalent COVID-19 booster

The application was based on preclinical data and clinical trial data available from a phase 2/3 study evaluation of the company's BA.1 Omicron-targeting bivalent booster candidate

- PMLiVE

Pfizer and BioNTech granted FDA Emergency Use Authorisation for BA.4/BA.5 COVID-19 booster

The companies outlined that the original and bivalent vaccines will be supplied under their existing supply agreement with the US government

- PMLiVE

Novavax’s COVID-19 vaccine candidate approved by MHRA for adolescents aged 12 to 17

Data from an ongoing phase 3 paediatric trial demonstrated Nuvaxovid produced 80% clinical efficacy in this age group

- PMLiVE

AstraZeneca’s Farxiga data shows ‘significant’ mortality benefits in heart failure patients

The pre-specified pooled analysis from two phase 3 trials demonstrated a reduction in cardiovascular death by 14%

- PMLiVE

Moderna sues Pfizer/BioNTech over COVID-19 vaccine technology

The company believes two key features of its patented mRNA technology platform were copied

- PMLiVE

Study found Pfizer’s Paxlovid only helped over 65s avoid hospitalisation and death

Researchers studied data from 109,000 patients – nearly all of whom had been vaccinated against COVID-19, been previously infected, or both

- PMLiVE

Moderna seeks FDA Emergency Use Authorisation for BA.4/BA.5 COVID-19 booster

The application is based on preclinical data and clinical trial data available from a phase 2/3 study evaluation of the company's BA.1 Omicron-targeting bivalent booster candidate

- PMLiVE

Pfizer and BioNTech release COVID-19 vaccine trial results for children under five

The phase 2/3 trial results showed that the vaccine was 73.2% effective in protecting children aged six months to four years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links